ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
“ESMO Rare Cancers25: Jean-Yves Blay discusses how the use of Real World Data has evolved to fill information gaps in sarcoma research, which have arisen due to the rarity and heterogeneity of subtypes and a lack of trial data.
Now more trusted by regulators, the role of real-world data may grow even further if challenges are addressed including ensuring accurate sarcoma diagnosis, improving access to reference centres and guideline-directed treatments, and standardising data collection.
To learn more, read his Editorial in the ESMO Daily Reporter.”
More posts featuring ESMO.